Skip to main content
All lobbying filings

Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical, Inc. filed a Q3 report for Otsuka America Pharmaceutical, Inc. on October 16, 2025.

Lobbying for Otsuka America Pharmaceutical, Inc.

As filed: OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.

All filings by Otsuka America Pharmaceutical, Inc. · Everything Otsuka America Pharmaceutical, Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 16, 2025
Expenses
$340,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Maryland

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6

Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.

Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act relating to pharmaceuticals.

Provisions related to pharmaceuticals in Continuing Appropriations and Other Matters Act, 2025, and provisions in H.R. 1, the One Big Beautiful Bill Act concerning appropriations for the Department of Health & Human Services and the Department of Veterans Affairs related to mental health and PTSD.

Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues, including provisions in H.R. 1, the One Big Beautiful Bill Act, relating to corporate tax rates and international business taxes.

Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.

Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.

 Bills named in this filing 3
  • S. 832
    EPIC Act of 2025
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • H.R. 1
    One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem